Archives
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
br AR signals and chemosensitivity in urothelial cancer A si
2024-08-05

AR signals and chemosensitivity in urothelial cancer A significant amount of patients with urothelial cancer fail to respond to cisplatin-based systemic chemotherapy, although it remains the mainstay of successful management of advanced disease. However, underlying mechanisms for chemoresistance
-
The SMN and SMN promoters are regulated by
2024-08-05

The SMN1 and SMN2 promoters are regulated by transcription factors such as E26 transformation-specific domain containing protein (ELK-1) and cAMP response element-binding protein (CREB) 58, 59. Compared with WT animals, mice with SMA exhibit increased and decreased ELK-1 and CREB phosphorylation, re
-
Preclinical models indicate roles for adiponectin in the mai
2024-08-05

Preclinical models indicate roles for adiponectin in the maintenance of hepatic lipid metabolism. Adiponectin overexpression prevents accumulation of triglycerides or the deleterious lipid metabolites diacylglycerols or ceramides [5,8]. Direct manipulation of adiponectin expression demonstrates a po
-
Synthesis pharmacological evaluation for the binding at hA h
2024-08-05

Synthesis, pharmacological evaluation for the binding at hA, hA and hA ARs, and efficacy at hA subtype of the synthesized compounds, together with the assessment of their theoretical ADME properties were the guidelines in this preliminary drug discovery investigation. The synthetic pathways which y
-
Materials and methods br Results br Discussion The BV tag
2024-08-03

Materials and methods Results Discussion The BV-tag-based electrochemiluminescence immunoassay is an extremely sensitive assay. It has been employed for detecting analytes present in only picogram quantities (e.g., bacterial toxins [26], 2-APB [19]), measuring the activity of basic carboxype
-
br Methods br Transparency document br
2024-08-03

Methods Transparency document Introduction Epinephrine (EP) is a critical hormone and catecholamine neurotransmitter in nervous system of mammals.1, 2, 3 It has been known to accelerate and regulate heartbeat, blood pressure, bronchodilation, mydriasis, blood sugar and lipolysis, and can he
-
The first rationally designed dual mPGES LO inhibitor
2024-08-03

The first rationally designed dual mPGES-1/5-LO inhibitor was reported in 2008 and represents a structural derivative of pirinixic cftr channel - a synthetic agonist of PPARα with lipid-lowering properties (Koeberle et al., 2008b). Further α-alkyl- and α-aryl-substituted derivatives have been synth
-
Matthew et al synthesized and carried
2024-08-03

Matthew et al. synthesized and carried out SAR studies of imidazo-[1,2-a]-pyrazine as Aurora kinase inhibitors with enhanced kinase selectivity and found that Marizomib 39 showed optimal potency on Aurora-A and Aurora-B with IC50 value of 4 nM and 13 nM while on phosphorylation histone H3 (pHH3), EC
-
br Extracellular domain architecture The extracellular regio
2024-08-03

Extracellular domain architecture The extracellular region of GABAB receptor exists in a heterodimeric configuration regardless of interactions within the rest of the protein (Geng et al., 2012, Liu et al., 2004, Nomura et al., 2008). The extracellular domains of the GABAB1 and GABAB2 subunits ar
-
These recommendations may be useful for the
2024-08-03

These recommendations may be useful for the future to avoid misleading reports and pairings. However, the existing literature can also hold back current research on some given orphans. Before entering into drug development or further physiological conceptual framework, these pairings should be thoro
-
br Declarations Funding None for the paper in question
2024-08-03

Declarations Funding: None for the paper in question. Competing interests: Florent Morio has received speaker's fees from Gilead, Basilea, and MSD and travel grants from Gilead, MSD, Pfizer, Basilea, and Astellas. Ethical approval: Not relevant for the paper in question. Introduction Lactic
-
Pathological angiogenesis occurs when an imbalance of endoge
2024-08-03

Pathological angiogenesis occurs when an imbalance of endogenous proangiogenic and antiangiogenic factors occurs. Although the focus of angiogenesis-related drug development has been geared to the discovery of antiangiogenic compounds for use in pathologies where excessive angiogenesis occurs (cance
-
It has been known for a while that oxygenation the
2024-08-03

It has been known for a while that oxygenation (the addition of oxygen) of Aβ can inhibit the formation of amyloids and diminish their cytotoxicity. Photo-oxygenation of Aβ started with fullerenes almost a decade ago by Toshima and co-workers. Later, porphyrins and polyoxometalates were used as well
-
br Neurological development and BCAAs Glutamate is an import
2024-08-02

Neurological development and BCAAs Glutamate is an important excitatory neurotransmitter in the brain, and BCAAs (especially leucine) function to synthesize glutamate in astrocytes around neurons, since leucine enters the brain from the blood more rapidly than other Exo1 synthesis and provides ∼
-
br Results and discussion br Conclusion The tyrosine
2024-08-02

Results and discussion Conclusion The tyrosine kinase ALK represents one of the most successful molecular targets for the development of precise medicine to treat stratified subgroups of cancer patients. Three generations of ALK inhibitors have been awarded the FDA's approval or are being exte
16020 records 115/1068 page Previous Next First page 上5页 111112113114115 下5页 Last page